Control of Lineage Commitment in Developing Thymocytes
胸腺细胞发育中谱系定型的控制
基本信息
- 批准号:8119148
- 负责人:
- 金额:$ 43.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-06-01 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAdultAffectAffinityAgeAnimalsAntibodiesBlood CellsCD4 Positive T LymphocytesCD44 geneCD8B1 geneCell Differentiation processCell LineageCell MaturationCellsCessation of lifeCharacteristicsChildhood LeukemiaDataDefectDevelopmentDiseaseEmployee StrikesEventExhibitsFetusGeneticGenetic TranscriptionGrowthHealthHematopoieticHumanIn VitroIncidenceLigandsLymphoidLymphomaLymphomagenesisMaintenanceMalignant NeoplasmsMediatingMediator of activation proteinModelingMonoclonal Antibody HuM291MusMutationOncogenesPhenotypePhysiologicalPlayPopulationProcessRegulatory ElementReporterRoleSeriesSignal TransductionStagingT-Cell DevelopmentT-LymphocyteTestingThymic LymphomaThymocyte DevelopmentThymocyte SelectionThymus GlandTransgenesTransgenic MiceTransgenic OrganismsTrue Thymic HyperplasiaTumor Suppressor GenesUrsidae Familybasecell typefetalin uteroin vivoin vivo Modelmonolayernovelprematurepublic health relevanceresearch studyresponsesingle cell analysisthymocytetranscription factortumortumor initiation
项目摘要
DESCRIPTION (provided by applicant): Hitherto, the expression of ThPOK in T cell development was believed to be restricted to the ab T cell lineage, in particular to transitional CD4+8lo thymocytes and SP CD4 cells in the thymus and periphery. We now show that a subset of gdTCR+ thymocytes also expresses ThPOK, and that ThPOK expression correlates largely with expression of the activation marker CD44. Furthermore, ThPOK is expressed in KN6 gdTCR transgenic mice in the presence of high but not low affinity ligands. These observations suggest that ThPOK is induced in gd thymocytes in response to strong TCR signals. Significantly, HD-/- mice, which lack functional ThPOK, show a severe defect in development of mature gd thymocytes, while mice expressing ThPOK constitutively show a striking increase, establishing an important role for ThPOK in maturation and/or lineage commitment of gd cells. Given that the importance of TCR signaling and selection for gd development remains highly controversial, establishing a critical role for ThPOK in these processes would represent a significant advance. Hence in Aims 1 and 2 of the current proposal, we propose to address whether ThPOK induction in gd thymocytes is directly regulated by TCR signaling, and whether ThPOK controls positive/negative selection of gd thymocytes and/or commitment to the gd lineage. Interestingly, while ThPOK appears to be required for normal gd development, its expression in preTCR-expressing DN thymocytes leads to a high incidence of thymic lymphomas. In Aim 3 we propose to identify the cell type and stage in ontogeny at which lymphomagenesis is initiated, and test whether gdTCR expression or gd commitment are sufficient to protect DN thymocytes against ThPOK-mediated lymphomagenesis.
PUBLIC HEALTH RELEVANCE: The current proposal deals with the process by which T cells develop to the distinct gd lineage, which we show is controlled by a key transcription factor called ThPOK. How ThPOK controls this process is unknown and the subject of this proposal. Unregulated expression of ThPOK causes blood cell cancer, so that understanding its function is of direct relevance to health.
描述(由申请人提供):目前,ThPOK在T细胞发育中的表达被认为限于ab T细胞谱系,特别是胸腺和外周中的过渡性CD 4 +8lo胸腺细胞和SP CD 4细胞。我们现在表明,一个子集的gdTCR+胸腺细胞也表达ThPOK,和ThPOK的表达在很大程度上与活化标志物CD 44的表达相关。此外,ThPOK在存在高而非低亲和力配体的情况下在KN 6 gdTCR转基因小鼠中表达。这些观察结果表明,ThPOK在gd胸腺细胞中响应强TCR信号而被诱导。值得注意的是,缺乏功能性ThPOK的HD-/-小鼠在成熟gd胸腺细胞的发育中显示出严重缺陷,而组成性表达ThPOK的小鼠显示出显著增加,确立了ThPOK在gd细胞成熟和/或谱系定型中的重要作用。鉴于TCR信号传导和选择对gd发育的重要性仍然存在高度争议,建立ThPOK在这些过程中的关键作用将代表一个重大进展。因此,在当前提案的目的1和2中,我们提出解决gd胸腺细胞中的ThPOK诱导是否直接受TCR信号传导调节,以及ThPOK是否控制gd胸腺细胞的正/负选择和/或对gd谱系的定型。有趣的是,虽然ThPOK似乎是正常gd发育所需的,但其在表达前TCR的DN胸腺细胞中的表达导致胸腺淋巴瘤的高发病率。在目的3中,我们提出了确定淋巴瘤发生启动的细胞类型和个体发育阶段,并测试gdTCR表达或gd定型是否足以保护DN胸腺细胞免受ThPOK介导的淋巴瘤发生。
公共卫生关系:目前的提议涉及T细胞发育为不同的gd谱系的过程,我们表明这是由一种称为ThPOK的关键转录因子控制的。ThPOK如何控制这一过程是未知的,也是本提案的主题。ThPOK的不受调节的表达导致血细胞癌,因此了解其功能与健康直接相关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dietmar J Kappes其他文献
CD4-CD8 lineage commitment: an inside view
CD4-CD8 谱系承诺:内部视角
- DOI:
10.1038/ni1230 - 发表时间:
2005-07-20 - 期刊:
- 影响因子:27.600
- 作者:
Dietmar J Kappes;Xiao He;Xi He - 通讯作者:
Xi He
ERK2 Substrate Binding Domains Play Distinct Roles in Megakaryocytic-Erythroid Lineage Progression and Mediates Clonal Fitness in Myeloproliferative Neoplasms
- DOI:
10.1182/blood-2022-170264 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Billy Truong;Yong Zhang;Esteban Martinez;Brianna Trankle;Anna-Mariya Kukuyan;Susan Shinton;James Oesterling;Xiang Hua;Dietmar J Kappes;Joan Font-Burgada;Tomasz Skorski;David Wiest - 通讯作者:
David Wiest
New ingredients for brewing CD4+T (cells): TCF-1 and LEF-1
用于酿造 CD4+T(细胞)的新成分:TCF-1 和 LEF-1
- DOI:
10.1038/ni.2927 - 发表时间:
2014-06-18 - 期刊:
- 影响因子:27.600
- 作者:
Jayati Mookerjee-Basu;Dietmar J Kappes - 通讯作者:
Dietmar J Kappes
Dietmar J Kappes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dietmar J Kappes', 18)}}的其他基金
Role of ThPOK in HSC Maintenance and Leukemogenesis
ThPOK 在 HSC 维持和白血病发生中的作用
- 批准号:
9025082 - 财政年份:2015
- 资助金额:
$ 43.93万 - 项目类别:
Dissecting Distinct and Redundant Roles of ThPOK and LRF, Key Regulators of Hematopoiesis
剖析造血关键调节因子 ThPOK 和 LRF 的不同和冗余作用
- 批准号:
9130273 - 财政年份:2015
- 资助金额:
$ 43.93万 - 项目类别:
Dissecting the role of ThPOK in thymic development and T cell differentiation
剖析 ThPOK 在胸腺发育和 T 细胞分化中的作用
- 批准号:
9322576 - 财政年份:2014
- 资助金额:
$ 43.93万 - 项目类别:
Dissecting the role of ThPOK in thymic development and T cell differentiation
剖析 ThPOK 在胸腺发育和 T 细胞分化中的作用
- 批准号:
8704657 - 财政年份:2014
- 资助金额:
$ 43.93万 - 项目类别:
Molecular Triggers of T Helper Lineage Choice
T 辅助细胞谱系选择的分子触发因素
- 批准号:
7508052 - 财政年份:2009
- 资助金额:
$ 43.93万 - 项目类别:
Molecular Triggers of T Helper Lineage Choice
T 辅助细胞谱系选择的分子触发因素
- 批准号:
7847576 - 财政年份:2009
- 资助金额:
$ 43.93万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 43.93万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 43.93万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 43.93万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 43.93万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 43.93万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 43.93万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 43.93万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 43.93万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 43.93万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 43.93万 - 项目类别:














{{item.name}}会员




